My background is chemistry rather than physiology, which may explain where I am stuck.
This is not behaving the way I expected and I want to understand the discrepancy before I act on it.
I have photographed the current state and recorded the conditions, so I can answer follow-up questions precisely.
Should I be treating this as a failure or as noise?
The half-life of roughly one week means steady state takes four to five weeks, which is why titration intervals are set at four.
The elimination half-life is approximately 165 to 184 hours — about a week — so steady state is reached after four to five weeks and any dose change takes that long to express itself fully.
The STEP programme covers weight management, SUSTAIN covers glycaemia, SELECT covers cardiovascular outcomes in the without-diabetes population, FLOW covers kidney outcomes and ESSENCE covers MASH. Quoting across these is the most common citation error on this tag.
The albumin-binding acylation strategy is shared with liraglutide, which uses a shorter C16 chain and consequently has a daily rather than weekly profile.
Nothing here is medical advice.
One-week half-life means four to five weeks to steady state. Titration intervals follow from that.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe honest answer is that the evidence base here is the deepest in the class and that depth is the main reason to reach for it as a reference point.
STEP-1 reported mean weight reduction of about fifteen per cent at 68 weeks on 2.4 mg against roughly two and a half per cent on placebo, in adults with obesity and without diabetes.
Stated carefully, oral semaglutide at 7 and 14 mg daily produces exposures comparable to lower weekly injectable doses, which is why the milligram figures are not comparable across routes.
The C18 diacid and the position-8 substitution are the two facts worth memorising.
Start with which indication and which dose, because the same molecule is licensed at different strengths for glycaemia and for weight and the trial evidence is separate.
Independent testing services publish more results on this molecule than on any other in the market, which makes lot-level checking unusually practical here.
Licensed weekly doses run 0.25, 0.5, 1.0, 1.7 and 2.4 mg depending on indication and product, with the 0.25 mg step being an initiation dose that is not intended to be therapeutic.
Published purity data on this molecule across the independent testing services is deep enough to make supplier-level comparison meaningful, which is not true of every compound.
Oral and injectable milligrams are not comparable. Exposures are.
Weight and glycaemic effects have different dose-response curves, which is why the licensed strengths differ by indication.
Structurally: alanine at position 8 replaced with alpha-aminoisobutyric acid to resist dipeptidyl peptidase-4, lysine at position 34 replaced by arginine, and a C18 fatty diacid attached at position 26 through a short spacer. The last of those gives the albumin binding and the weekly half-life.
A molecule being well studied does not make an unverified vial of it well characterised.
If you are testing a lot, this is the molecule with the most published comparators to test it against.
This is the agent with the most published independent testing data in the research-compound market, which is a separate consideration from the clinical evidence.
Reconstitution and dilution arithmetic for research-grade lyophilised material is unaffected by any of this: concentration is content divided by diluent volume, and content is not the same as label claim.
FLOW is the dedicated kidney-outcome trial and ESSENCE the MASH programme; both are semaglutide trials and neither is a tirzepatide trial.
Name the trial programme with the claim: STEP, SUSTAIN, SELECT, FLOW and ESSENCE answer different questions.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.